SAN DIEGO, June 29, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether BioXcel Therapeutics (NASDAQ: BTAI), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased BioXcel common stock? If you purchased BioXcel common stock and suffered significant losses on your investment, join our investigation now:
https://www.johnsonfistel.com/investigations/bioxcel-therapeutics
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471
There is no cost or obligation to you.
What is Johnson Fistel investigating? On June 29, 2023, BioXcel disclosed in a regulatory filing its Phase 3 trial for Alzheimer's successfully achieved its primary objective; however, investor concerns arose due to a principal investigator’s timeliness in reporting a serious adverse event. Along with this, the FDA uncovered a non-compliance issue at the site where the principal investigator enrolled around 40% of the participants in the study, known as TRANQUILITY II.
Following this news, BioXcel stock dropped 56% during premarket trading on June 29, 2023.
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.
Contact:
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471
Email: jimb@johnsonfistel.com
